{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:32:54Z","timestamp":1791639174650,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17J0844"],"award-info":[{"award-number":["JP17J0844"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Thalidomide and its derivatives exert not only therapeutic effects as immunomodulatory drugs (IMiDs) but also adverse effects such as teratogenicity, which are due in part to different C2H2 zinc-finger (ZF) transcription factors, IKZF1 (or IKZF3) and SALL4, respectively. Here, we report the structural bases for the SALL4-specific proteasomal degradation induced by 5-hydroxythalidomide, a primary thalidomide metabolite generated by the enzymatic activity of cytochrome P450 isozymes, through the interaction with cereblon (CRBN). The crystal structure of the metabolite-mediated human SALL4-CRBN complex and mutagenesis studies elucidate the complex formation enhanced by the interaction between CRBN and an additional hydroxy group of (\n                    <jats:italic>S<\/jats:italic>\n                    )-5-hydroxythalidomide and the variation in the second residue of \u03b2-hairpin structure that underlies the C2H2 ZF-type neo-morphic substrate (neosubstrate) selectivity of 5-hydroxythalidomide. These findings deepen our understanding of the pharmaceutical action of IMiDs and provide structural evidence that the glue-type E3 ligase modulators cause altered neosubstrate specificities through their metabolism.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-18488-4","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T06:03:01Z","timestamp":1600063381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide"],"prefix":"10.1038","volume":"11","author":[{"given":"Hirotake","family":"Furihata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-7481","authenticated-orcid":false,"given":"Satoshi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-4064","authenticated-orcid":false,"given":"Norio","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-2480","authenticated-orcid":false,"given":"Masaru","family":"Tanokura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-0556","authenticated-orcid":false,"given":"Tatsuya","family":"Sawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-3549","authenticated-orcid":false,"given":"Takuya","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"18488_CR1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","volume":"39","author":"M Melchert","year":"2007","unstructured":"Melchert, M. & List, A. The thalidomide saga. Int. J. Biochem. Cell. Biol. 39, 1489\u20131499 (2007).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"18488_CR2","first-page":"197","volume":"4","author":"W Lenz","year":"1968","unstructured":"Lenz, W. The susceptible period for thalidomide malformations in man and monkey. Ger. Med. Mon. 4, 197\u2013198 (1968).","journal-title":"Ger. Med. Mon."},{"key":"18488_CR3","first-page":"99","volume":"2","author":"W Lenz","year":"1996","unstructured":"Lenz, W. Malformations caused by drugs in pregnancy. Am. J. Dis. Child. 2, 99\u2013106 (1996).","journal-title":"Am. J. Dis. Child."},{"key":"18488_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/8371","volume":"5","author":"BF Hales","year":"1999","unstructured":"Hales, B. F. Thalidomide on the comeback trail. Nat. Med. 5, 489\u2013490 (1999).","journal-title":"Nat. Med."},{"key":"18488_CR5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565\u20131571 (1999).","journal-title":"N. Engl. J. Med."},{"key":"18488_CR6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett, J. B., Dredge, K. & Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314\u2013322 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"18488_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","volume":"136","author":"B Pan","year":"2012","unstructured":"Pan, B. & Lentzsch, S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol. Ther. 136, 56\u201368 (2012).","journal-title":"Pharmacol. Ther."},{"key":"18488_CR8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"18488_CR9","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"18488_CR10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","volume":"63","author":"JJ Higgins","year":"2004","unstructured":"Higgins, J. J., Pucilowska, J., Lombardi, R. Q. & Rooney, J. P. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63, 1927\u20131931 (2004).","journal-title":"Neurology"},{"key":"18488_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"18488_CR12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"18488_CR13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature05175","volume":"443","author":"S Angers","year":"2006","unstructured":"Angers, S. et al. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590\u2013593 (2006).","journal-title":"Nature"},{"key":"18488_CR14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrm.2016.91","volume":"17","author":"L Buetow","year":"2016","unstructured":"Buetow, L. & Huang, D. T. Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell. Biol. 17, 626\u2013642 (2016).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"18488_CR15","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771\u20134779 (2011).","journal-title":"Blood"},{"key":"18488_CR16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 CRBN. Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"18488_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"18488_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"18488_CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"18488_CR20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","volume":"48","author":"LB John","year":"2011","unstructured":"John, L. B. & Ward, A. C. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol. Immunol. 48, 1272\u20131278 (2011).","journal-title":"Mol. Immunol."},{"key":"18488_CR21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2007-07-098202","volume":"111","author":"M Dijon","year":"2008","unstructured":"Dijon, M. et al. The role of Ikaros in human erythroid differentiation. Blood 111, 1138\u20131146 (2008).","journal-title":"Blood"},{"key":"18488_CR22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thom\u00e4, N. H. Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4 CRBN ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"18488_CR23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4 CRBN ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"18488_CR24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, 558 (2018).","journal-title":"Science"},{"key":"18488_CR25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nbt.3128","volume":"33","author":"HS Najafabadi","year":"2015","unstructured":"Najafabadi, H. S. et al. C2H2 zinc finger proteins greatly expand the human regulatory lexicon. Nat. Biotechnol. 33, 555\u2013562 (2015).","journal-title":"Nat. Biotechnol."},{"key":"18488_CR26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"18488_CR27","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife 7, e38430 (2018).","journal-title":"eLife"},{"key":"18488_CR28","doi-asserted-by":"publisher","unstructured":"Yamanaka, S. et al. PLZF is a new substrate of CRBN with thalidomide and 5-hydroxythalidomide. Preprint at https:\/\/doi.org\/10.1101\/2020.02.28.969071 (2020).","DOI":"10.1101\/2020.02.28.969071"},{"key":"18488_CR29","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","volume":"15","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura, T. et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. 15, 1077\u20131084 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"18488_CR30","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1073\/pnas.1421949112","volume":"112","author":"R Akiyama","year":"2015","unstructured":"Akiyama, R. et al. Sall4-Gli3 system in early limb progenitors is essential for the development of limb skeletal elements. Proc. Natl Acad. Sci. USA 112, 5075\u20135080 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18488_CR31","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/hmg\/11.23.2979","volume":"11","author":"J Kohlhase","year":"2002","unstructured":"Kohlhase, J. et al. Okihiro syndrome is caused by SALL4 mutations. Hum. Mol. Genet. 11, 2979\u20132987 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"18488_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng1707","volume":"38","author":"K Koshiba-Takeuchi","year":"2006","unstructured":"Koshiba-Takeuchi, K. et al. Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart. Nat. Genet. 38, 175\u2013183 (2006).","journal-title":"Nat. Genet."},{"key":"18488_CR33","doi-asserted-by":"crossref","first-page":"16319","DOI":"10.1073\/pnas.0607884103","volume":"103","author":"U Elling","year":"2006","unstructured":"Elling, U., Klasen, C., Eisenberger, T., Anlag, K. & Treier, M. Murine inner cell mass-derived lineages depend on Sall4 function. Proc. Natl Acad. Sci. USA 103, 16319\u201316324 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18488_CR34","first-page":"1964","volume":"8","author":"Y Ando","year":"2002","unstructured":"Ando, Y., Fuse, E. & Figg, W. D. Thalidomide metabolism by CYP2C subfamily. Clin. Cancer Res. 8, 1964\u20131973 (2002).","journal-title":"Clin. Cancer Res."},{"key":"18488_CR35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/tx900367p","volume":"23","author":"G Chowdhury","year":"2010","unstructured":"Chowdhury, G. et al. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formulation of a glutathione conjugate. Chem. Res. Toxicol. 23, 1018\u20131024 (2010).","journal-title":"Chem. Res. Toxicol."},{"key":"18488_CR36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/tx300009j","volume":"25","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki, H. et al. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem. Res. Toxicol. 25, 274\u2013276 (2012).","journal-title":"Chem. Res. Toxicol."},{"key":"18488_CR37","volume":"8","author":"T Mori","year":"2018","unstructured":"Mori, T. et al. Structural basis of thalidomide enantiomer binding to cereblon. Sci. Rep. 8, 1294 (2018).","journal-title":"Sci. Rep."},{"key":"18488_CR38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ympev.2019.03.001","volume":"135","author":"W Onodera","year":"2019","unstructured":"Onodera, W., Asahi, T. & Sawamura, N. Positive selection of cereblon modified function including its E3 ubiquitin ligase activity and binding efficiency with AMPK. Mol. Phylogenet. Evol. 135, 78\u201385 (2019).","journal-title":"Mol. Phylogenet. Evol."},{"key":"18488_CR39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela, M. E. et al. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex. Nat. Struct. Mol. Biol. 27, 319\u2013322 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"18488_CR40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0041-008X(65)90095-5","volume":"7","author":"ID Fratta","year":"1965","unstructured":"Fratta, I. D., Sigg, E. B. & Maiorana, K. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol. Appl. Pharmacol. 7, 268\u2013286 (1965).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"18488_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/tx4004215","volume":"27","author":"G Chowdhury","year":"2014","unstructured":"Chowdhury, G., Shibata, N., Yamazaki, H. & Guengerich, F. G. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem. Res. Toxicol. 27, 147\u2013156 (2014).","journal-title":"Chem. Res. Toxicol."},{"key":"18488_CR42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","volume":"71","author":"M Hoffmann","year":"2013","unstructured":"Hoffmann, M. et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother. Pharmacol. 71, 489\u2013501 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"18488_CR43","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/00498254.2016.1247218","volume":"47","author":"M Shimizu","year":"2017","unstructured":"Shimizu, M. et al. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica 47, 844\u2013848 (2017).","journal-title":"Xenobiotica"},{"key":"18488_CR44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","volume":"14","author":"RP Nowak","year":"2018","unstructured":"Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem. Biol. 14, 706\u2013714 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"18488_CR45","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.bmcl.2009.02.108","volume":"19","author":"T Yamamoto","year":"2009","unstructured":"Yamamoto, T. et al. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg. Med. Chem. Lett. 19, 3973\u20133976 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"18488_CR46","doi-asserted-by":"crossref","first-page":"e0156716","DOI":"10.1371\/journal.pone.0156716","volume":"11","author":"T Yano","year":"2016","unstructured":"Yano, T. et al. AGIA tag system based on a high affinity rabbit monoclonal antibody against human dopamine receptor D1 for protein analysis. PLoS ONE 11, e0156716 (2016).","journal-title":"PLoS ONE"},{"key":"18488_CR47","doi-asserted-by":"crossref","first-page":"14652","DOI":"10.1073\/pnas.232580399","volume":"99","author":"T Sawasaki","year":"2002","unstructured":"Sawasaki, T., Ogasawara, T., Morishita, R. & Endo, Y. A cell-free protein synthesis system for high-throughput proteomics. Proc. Natl Acad. Sci. USA 99, 14652\u201314657 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18488_CR48","doi-asserted-by":"crossref","first-page":"e0156718","DOI":"10.1371\/journal.pone.0156718","volume":"11","author":"H Takahashi","year":"2016","unstructured":"Takahashi, H. et al. Establishment of a wheat cell-free synthesized protein array containing 250 human and mouse E3 ubiquitin ligases to identify novel interaction between E3 ligases and substrate proteins. PLoS ONE 11, e0156718 (2016).","journal-title":"PLoS ONE"},{"key":"18488_CR49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.febslet.2007.12.004","volume":"582","author":"T Sawasaki","year":"2008","unstructured":"Sawasaki, T. et al. Arabidopsis HY5 protein functions as a DNA-binding tag for purification and functional immobilization of proteins on agarose\/DNA microplate. FEBS Lett. 582, 221\u2013228 (2008).","journal-title":"FEBS Lett."},{"key":"18488_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"18488_CR51","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D"},{"key":"18488_CR52","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"18488_CR53","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D"},{"key":"18488_CR54","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","volume":"58","author":"PD Adams","year":"2002","unstructured":"Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948\u20131954 (2002).","journal-title":"Acta Crystallogr. D"},{"key":"18488_CR55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. Molprovity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"18488_CR56","doi-asserted-by":"crossref","unstructured":"Yamanaka, S. et al. An IMiD-induced SALL4 degron system for selective degradation of target proteins. Commun. Biol. (2020, in press).","DOI":"10.1038\/s42003-020-01240-5"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18488-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:24:05Z","timestamp":1670271845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18488-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18488"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18488-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4578"}}